APP and Alzheimer disease: In order to expand the knowledge space around AD biomarkers, we need to specifically address the so-called ‘gray zone’ that is rich in speculation and hints for emerging knowledge and that exists outside of the well-established world of biomarker candidates such as Tau and APP.